Predictors of functional decline in early Parkinson's Disease: NET-PD LS1 Cohort

Journal of Parkinson's Disease

Volumn 5, Issue 4, 2015, Pages 773-782

  Bega, Danny ^a   Kim, Soeun ^b   Zhang, Yunxi ^b   Elm, Jordan ^c   Schneider, Jay ^d   Hauser, Robert ^e   Fraser, Andy ^f   Simuni, Tanya ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

^e UNIVERSITY OF SOUTH FLORIDA   (United States)

^f OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

NET PD; Parkinsons disease

Indexed keywords

CREATINE; LEVODOPA; ANTIPARKINSON AGENT;

ACTIVITY OF DAILY LIVING ASSESSMENT; ADULT; AMBULATORY CAPACITY SCORE; ARTICLE; BODY MASS; COHORT ANALYSIS; CONTROLLED STUDY; DETERIORATION; FEMALE; FUNCTIONAL STATUS; FUNCTIONAL STATUS ASSESSMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY (TOPIC); NEUROLOGIC DISEASE ASSESSMENT; PARKINSON DISEASE; PD 39 ITEM QUESTIONNAIRE; PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTIVE VALUE; PRIORITY JOURNAL; RANKIN SCALE; SCALE FOR OUTCOMESOF PARKINSON DISEASE COGNITION SCORE; SCHWAB AND ENGLAND ADL SCALE; SYMBOL DIGIT MODALITIES TEST; UNIFIED PARKINSON DISEASE RATING SCALE; AGED; CLINICAL TRIAL; DAILY LIFE ACTIVITY; DISEASE COURSE; LONGITUDINAL STUDY; MULTICENTER STUDY; NATIONAL HEALTH ORGANIZATION; ONSET AGE; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PROCEDURES; PROGNOSIS; SEVERITY OF ILLNESS INDEX; UNITED STATES;

ACTIVITIES OF DAILY LIVING; AGE OF ONSET; AGED; ANTIPARKINSON AGENTS; DISEASE PROGRESSION; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE; OUTCOME ASSESSMENT (HEALTH CARE); PARKINSON DISEASE; PROGNOSIS; SEVERITY OF ILLNESS INDEX; UNITED STATES;

EID: 84952644705     PISSN: 18777171     EISSN: 1877718X     Source Type: Journal    
DOI: 10.3233/JPD-150668     Document Type: Article

References (43)

1. Alves G, Wentzel-Larsen T, Aarsland D, Larsen JP, 2005 Progression of motor impairment and disability in Parkinson disease: A population-based study. Neurology 65 1436 1441
2. Goetz CG, Stebbins GT, Blasucci LM, 2000 Differential progression of motor impairment in levodopa-treated Parkinson's disease. Mov Disord 15 479 484
3. Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG, 2008 The Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years. Mov Disord 23 837 844
4. Jankovic J, Kapadia AS, 2001 Functional decline in Parkinson disease. Arch Neurol 58 1611 1615
5. Louis ED, Tang MX, Cote L, Alfaro B, Mejia H, Marder K, 1999 Progression of parkinsonian signs in Parkinson disease. Arch Neurol 56 334 337
6. Marras C, McDermott MP, Marek K, Rochon P, Naglie G, Tanner CM, Rudolph A, Shoulson I, Lang AE, Parkinson Study Group D, & investigators P 2011 Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts. Mov Disord 26 608 613
7. Marras C, McDermott MP, Rochon PA, Tanner CM, Naglie G, Lang AE, Parkinson Study Group DI 2008 Predictors of deterioration in health-related quality of life in Parkinson's disease: Results from the DATATOP trial. Mov Disord 23 653 659. quiz, 776.
8. Marras C, Rochon P, Lang AE, 2002 Predicting motor decline and disability in Parkinson disease: A systematic review. Arch Neurol 59 1724 1728
9. Parashos SA, Luo S, Biglan KM, Bodis-Wollner I, He B, Liang GS, Ross GW, Tilley BC, Shulman LM, Investigators N-P 2014 Measuring disease progression in early Parkinson disease: The National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience. JAMA Neurol 71 710 716
10. Post B, Merkus MP, de Haan RJ, Speelman JD, Group CS, 2007 Prognostic factors for the progression of Parkinson's disease: A systematic review. Mov Disord 22 1839 1851. quiz, 1988 1988
11. Post B, Muslimovic D, van Geloven N, Speelman JD, Schmand B, de Haan RJ, group CA-s 2011 Progression and prognostic factors of motor impairment, disability and quality of life in newly diagnosed Parkinson's disease. Mov Disord 26 449 456
12. Schrag A, Dodel R, Spottke A, Bornschein B, Siebert U, Quinn NP, 2007 Rate of clinical progression inParkinson's disease. A prospective study. Mov Disord 22 938 945
13. Schwarzschild MA, Schwid SR, Marek K, Watts A, Lang AE, Oakes D, Shoulson I, Ascherio A, Parkinson Study Group PI Hyson C, Gorbold E, Rudolph A, Kieburtz K, Fahn S, Gauger L, Goetz C, Seibyl J, Forrest M, Ondrasik J, 2008 Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol 65 716 723
14. Starkstein SE, Mayberg HS, Leiguarda R, Preziosi TJ, Robinson RG, 1992 A prospective longitudinal study of depression, cognitive decline, and physical impairments in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 55 377 382
15. Williams-Gray CH, Mason SL, Evans JR, Foltynie T, Brayne C, Robbins TW, Barker RA, 2013 The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort. J Neurol Neurosurg Psychiatry 84 1258 1264
16. Suchowersky O, Reich S, Perlmutter J, Zesiewicz T, Gronseth G, Weiner WJ, Quality Standards Subcommittee of the American Academy of N 2006 Practice Parameter: Diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 66 968 975
17. Elm JJ, Investigators NN-P 2012 Design innovations and baseline findings in a long-term Parkinson's trial: The National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson's Disease Long-Term Study-1. Mov Disord 27 1513 1521
18. Writing Group for the NETiPDI Kieburtz K, Tilley BC, Elm JJ, Babcock D, Hauser R, Ross GW, Augustine AH, Augustine EU, Aminoff MJ, Bodis-Wollner IG, Boyd J, Cambi F, Chou K, Christine CW, Cines M, Dahodwala N, Derwent L, Dewey RB Jr, Hawthorne K, Houghton DJ, Kamp C, Leehey M, Lew MF, Liang GS, Luo ST, Mari Z, Morgan JC, Parashos S, Perez A, Petrovitch H, Rajan S, Reichwein S, Roth JT, Schneider JS, Shannon KM, Simon DK, Simuni T, Singer C, Sudarsky L, Tanner CM, Umeh CC, Williams K, Wills AM, 2015 Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: A randomized clinical trial. JAMA 313 584 593
19. Huang P, Goetz CG, Woolson RF, Tilley B, Kerr D, Palesch Y, Elm J, Ravina B, Bergmann KJ, Kieburtz K, Parkinson Study G 2009 Using global statistical tests in long-term Parkinson's disease clinical trials. Mov Disord 24 1732 1739
20. McRae C, Diem G, Vo A, O'Brien C, Seeberger L, 2000 Schwab & England: Standardization of administration. Mov Disord 15 335 336
21. Jenkinson C, Fitzpatrick R, Norquist J, Findley L, Hughes K, 2003 Cross-cultural evaluation of the Parkinson's Disease Questionnaire: Tests of data quality, score reliability, response rate, and scaling assumptions in the United States, Canada, Japan, Italy, and Spain. J Clin Epidemiol 56 843 847
22. Goetz CG, Stebbins GT, Chmura TA, Fahn S, Klawans HL, Marsden CD, 1995 Teaching tape for the motor section of the unified Parkinson's disease rating scale. Mov Disord 10 263 266
23. Sheridan LK, Fitzgerald HE, Adams KM, Nigg JT, Martel MM, Puttler LI, Wong MM, Zucker RA, 2006 Normative Symbol Digit Modalities Test performance in a community-based sample. Arch Clin Neuropsychol 21 23 28
24. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J, 1988 Interobserver agreement for the assessment of handicap in stroke patients. Stroke 19 604 607
25. Beck AT, Steer RA, Ball R, Ranieri W, 1996 Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients. J Pers Assess 67 588 597
26. Shoulson I, Kurlan R, Rubin A, 1990 Quantification of Neurologic Deficit. J Neurol Neurosurg Psychiatr 53 628
27. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE, 2010 Systematic review of levodopa doseequivalency reporting in Parkinson's disease. Mov Disord 25 2649 2653
28. Jankovic J, McDermott M, Carter J, Gauthier S, Goetz C, Golbe L, Huber S, Koller W, Olanow C, Shoulson I, 1990 Variable expression of Parkinson's disease: A base-line analysis of the DATATOP cohort. The Parkinson Study Group. Neurology 40 1529 1534
29. Marinus J, Visser M, Verwey NA, Verhey FR, Middelkoop HA, Stiggelbout AM, van Hilten JJ, 2003 Assessment of cognition in Parkinson's disease. Neurology 61 1222 1228
30. Siderowf AD, Werner RM, 2001 The EQ-5D-a generic quality of life measure-is a useful instrument to measurequality of life in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 70 817
31. Kramer M, R2 statistics for mixed models, http://afrsweb.usda.gov/sp2userfiles/ad-hoc/12000000spatialworkshop/19kramersupplrsq.pdf
32. Hoehn MM, Yahr MD, 1967 Parkinsonism: Onset, progression and mortality. Neurology 17 427 442
33. McDermott MP, Jankovic J, Carter J, Fahn S, Gauthier S, Goetz CG, Golbe LI, Koller W, Lang AE, Olanow CW, 1995 Factors predictive of the need for levodopa therapy in early, untreated Parkinson's disease. The Parkinson Study Group. Arch Neurol 52 565 570
34. Reinoso G, Allen JC Jr, Au WL, Seah SH, Tay KY, Tan LC, 2015 Clinical evolution of Parkinson's disease and prognostic factors affecting motor progression: 9-year follow-up study. Eur J Neurol 22 457 463
35. Vu TC, Nutt JG, Holford NH, 2012 Disease progress and response to treatment as predictors of survival, disability, cognitive impairment and depression in Parkinson's disease. Br J Clin Pharmacol 74 284 295
36. Braak H, Rub U, Jansen Steur EN, Del Tredici K, de Vos RA, 2005 Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology 64 1404 1410
37. Dissanayaka NN, Sellbach A, Silburn PA, O'Sullivan JD, Marsh R, Mellick GD, 2011 Factors associated with depression in Parkinson's disease. J Affect Disord 132 82 88
38. Ravina B, Camicioli R, Como PG, Marsh L, Jankovic J, Weintraub D, Elm J, 2007 The impact of depressive symptoms in early Parkinson disease. Neurology 69 342 347
39. Leentjens AF, Verhey FR, Luijckx GJ, Troost J, 2000 The validity of the Beck Depression Inventory as a screening and diagnostic instrument for depression in patients with Parkinson's disease. Mov Disord 15 1221 1224
40. Hauser R, Rascol O, Olanow W, Stocchi F, 2014 Effects of long-term rasagiline treatment on time to key PD milestones: Results from the ADAGIO follow-up (AFU) study [abstract]. Movement Disorders 29
41. de Lau LM, Koudstaal PJ, Hofman A, Breteler MM, 2005 Serum uric acid levels and the risk of Parkinson disease. Ann Neurol 58 797 800
42. Weisskopf MG, O'Reilly E, Chen H, Schwarzschild MA, Ascherio A, 2007 Plasma urate and risk of Parkinson's disease. Am J Epidemiol 166 561 567
43. Simuni T, Luo ST, Chou KL, Fernandez H, He B, Parashos S, 2013 Rankin scale as a potential measure of globaldisability in early Parkinson's disease. J Clin Neurosci 20 1200 1203